Syndax Pharmaceuticals, Inc.
SNDX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$20.56
▼ -0.58%
P/E
-8.16
Mkt Cap
$1.8B
52-Wk Range
$12.99–$25.59
52-Week Range
$12.99 - $25.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel Menin-MLL binding mechanism with limited competitive landscape
- Strategic partnerships with National Cancer Institute and major pharmaceutical companies
- Focused pipeline targeting high-unmet medical needs in oncology and immunology
- Experienced management team in precision medicine and clinical development
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Moderate growth ahead
Advancement of SNDX-5613 through Phase 1/2 trials in AML indications
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+21.2% over 3m
Quality
Excellent
High-growth business (222% revenue growth, 97% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying SNDX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 4, 2026
Reported EPS of -$0.55 vs -$0.45 consensus (-22.9% surprise). Revenue of $72.8M vs $79.4M expected (-8.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-22.9%
Revenue trend · last 8Q
—
—
—
+985%
+267%
+792%
+224%
+92%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$12.5M
$7.7M
$20.0M
$38.0M
$45.9M
$68.5M
$64.9M
$72.8M
Margins · last 8Q
Gross
95.6%
Operating
-55.0%
Profit
-67.8%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: UBS · Aug 21, 2026
vs Industry
How SNDX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related